Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome

被引：4
|
作者：
Yanada, Masamitsu [1 ]
Huang, Xuelin
Garcia-Manero, Guillermo
O'Brien, Susan
Ravandi, Farhad
Borthakur, Gautam
Faderl, Stefan
Issa, Jean-Pierre
Kantarjian, Hagop
Estey, Elihu
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukimia, Houston, TX 77025 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostatr, Houston, TX 77025 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 138卷 / 04期
关键词：
acute myeloid leukaemia; myelodysplastic syndrome; targeted therapy; haematological improvement; survival;
D O I：
10.1111/j.1365-2141.2007.06670.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：555 / 557
页数：3
相关论文
共 50 条
  • [41] Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Daver, Naval
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Brandt, Mark
    Pierce, Sherry
    Vaughan, Kenneth
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Patel, Keyur
    Jorgensen, Jeffery
    Pemmaraju, Naveen
    Kadia, Tapan
    Konopleva, Marina
    Andreeff, Michael
    DiNardo, Courtney
    Cortes, Jorge
    Ward, Renee
    Craig, Adam
    Ravandi, Farhad
    HAEMATOLOGICA, 2017, 102 (10) : 1709 - 1717
  • [42] Cladribine, Idarubicin, Cytarabine (araC), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    Andreeff, Michael
    Daver, Naval
    Jain, Nitin
    Kornblau, Steven M.
    Jabbour, Elias
    Short, Nicholas J.
    Alvarado, Yesid
    Ohanian, Maro
    Bose, Prithviraj
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2020, 136
  • [43] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 103 - 104
  • [44] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Villa, M. R.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Izzo, G. Nitrato
    Gagliardi, A.
    Mastrullo, L.
    HAEMATOLOGICA, 2017, 102 : 766 - 767
  • [45] Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Taborda, Cristian C.
    Gier, Shannon H.
    Stivale, Avery W.
    Perl, Alexander E.
    Gill, Saar
    Babushok, Daria, V
    Hexner, Elizabeth O.
    Frey, Noelle, V
    Lai, Catherine
    Bruno, Ximena Jordan
    Martin, Mary Ellen
    Maillard, Ivan
    Porter, David L.
    Loren, Alison W.
    Pratz, Keith W.
    Luger, Selina M.
    Gimotty, Phyllis A.
    McCurdy, Shannon R.
    BLOOD, 2022, 140 : 10825 - 10827
  • [46] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Esposito, M.
    Gagliardi, A.
    Lucania, A.
    Izzo, G. Nitrato
    Villa, M. R.
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2015, 39 : S52 - S53
  • [47] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Villa, M. R.
    Gagliardi, A.
    Della Cioppa, P.
    Esposito, M.
    Lucania, A.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2016, 101 : S120 - S121
  • [48] A Tertiary Center's Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Szakacs, Zsolt
    Kosztolanyi, Szabolcs
    Nagy, Agnes
    Pammer, Judit
    Kohl, Zoltan
    Alizadeh, Hussain
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S317 - S318
  • [49] Early diagnosis and targeted treatment of very high-risk childhood acute lymphoblastic leukaemia
    Breithaupt, P.
    Carlo, G.
    Schrauder, A.
    Meissner, B.
    Moericke, A.
    Bourqin, J. P.
    Schrappe, M.
    Stanulla, M.
    KLINISCHE PADIATRIE, 2009, 221 (03): : 195 - 195
  • [50] Posaconazole prophylaxis obviates the need for empirical escalation of antifungal therapy during chemotherapy for acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (HR-MDS)
    Roughley, C. A.
    Lindsay, J.
    Saied, K.
    Ratnayake, V.
    Pocock, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 60 - 60
12345